To evaluate the Springfusol'J infusion device for clinical use in an Intensive Care Unit and to compare the technique of intermittent bolus and constant infusion of muscle relaxants, we undertook a prospective double-blind randomized placebocontrolled study. Twenty critically ill ventilated patients requiring muscle paralysis were investigated. Although we could show no clinical advantage in infusing vecuronium, the Springfusol'J provided a more constant level of paralysis compared with hourly bolus doses. The device is robust, easy to use and reduces nursing workload. This may translate into cost-saving improvement in patient care if the Springfusol'J is used to provide muscle relaxation, sedation and analgesia.
vecuronium is 1.0 with normal saline being the standard'. To test the claims of the manufacturer in the clinical setting and to compare the efficacy of the Spring-fusor®, we undertook a double-blind placebocontrolled trial comparing vecuronium delivered by the Springfusor® to our present regime of hourly intermittent bolus doses.
Vecuronium (Norcuron®, Organon Teknika) is a medium-acting nondepolarising muscle relaxant and is the muscle relaxant most commonly used by anaesthesiologist intensivists in intensive care units in the United States'. In clinically used doses it has minimal Anaesthesia and Intensive Care, Vol. 22, No. 5, October, 1994 effect on the heart rate or blood pressure 4 and minimal histamine release'.
The secondary aim of the trial was to compare our standard practice of hourly bolus doses of vecuronium with a continuous infusion technique. Similar studies comparing bolus with continuous infusion of vecuronium have been conducted but none has used a double-blind placebo-controlled method 6 . 1O •
MATERIALS AND METHODS
The protocol was approved by the Hospital and University Ethics Committees and informed consent was obtained. Patients between the age of 18 and 65 years requiring muscle paralysis for ventilation for at least a further 24 hours were enrolled. Patients with neuromuscular disease, hepatic or renal failure, previous reaction to nondepolarising drugs, suspected toxin ingestion or pregnancy were excluded.
At 2000 hours on the preceding night all paralysis was discontinued and patients were commenced on a regimen of hourly bolus doses of vecuronium. An initial dose of 100-120 j-tg.kg-' was used. Additional doses of 1 mg pm were given if clinically indicated. An assessment was made of the total dose required in the previous hour and the dose increased or decreased accordingly until an appropriate hourly dose was reached ( Figure 2 ).
At 0800 hours the hourly dosage requirements for the period 0400 to 0759 were averaged and the resultant dose was used as the hourly dose for the trial period. Patients were randomized into two groups: 1. those receiving vecuronium from the Springfusor® infusion pump (SIP) and those receiving hourly intermittent bolus doses (HIB) of placebo, and 2. SIP with placebo and HIB with vecuronium. Following randomization drug syringes were prepared by the clinical pharmacist. The nursing staff were provided with three sets of syringes: an hourly bolus syringe (BS), a Spring-fusor® refill syringe (RS) and an emergency top-up syringe (ES). Nursing staff, the attending clinician, and the investigators were all blinded to the contents of the BS and RS. The ES contained vecuronium at the same concentration as the active syringe.
The Springfusor® syringe was filled and at 0900 hours connected to a free-running central venous line. A 10 ml syringe with tubing designated to give an infusion rate of 2.5 mllhr was chosen. Hourly bolus doses of 2.5 ml were given from the BS. Nursing staff were encouraged to follow their normal practice but instructed to record the administration time to the nearest minute. Springfusor® devices were checked at this time, the exact amount remaining in the syringe was recorded and the syringe was refilled when required. This data was used to calculate the flow rate of the Springfusor®.
Blood pressure, heart rate and the presence of respiratory effort, along with train-of-four counts (TOFC) were recorded from 1250 hours and repeated at 20 minute intervals until either 1730 hours or the Springfusor® infusion was exhausted. Tidal volumes and peak airway pressures of each patient were recorded at each interval, from the ventilator digital display (Elema Servo 900C Siemens, Sweden). Dynamic compliance was calculated by standard formulae.
Neuromuscular testing was performed with a Microstim Plus (Organon Teknika N.Y., Belgium) using cutaneous Ag/AgCI electrodes placed on the ulnar aspect of the lower forearm. Adductor pollicis movement was assessed for the TOFC, following the method described by Beemer et al".
Observations were made for movement and evidence of respiratory effort. The Mann Whitney test was used to test for significant differences in incidence of events.
All readings at 10 minutes (TlO), 30 minutes (T30) and 50 minutes (T50) past the hour for each patient were averaged. Results were analysed using a two-way analysis of variance (AN OVA) for the entire group and a one-way ANOVA for each of the two groups. P values less than 0.05 were considered significant.
RESULTS
Twenty-seven patients were enrolled to achieve ten patients in each group. Five patients enrolled in the trial were withdrawn the following morning as their clinically indicated doses of muscle relaxant had reached zero. Two further patients were withdrawn as the attending clinician felt paralysis was no longer indicated. There was no significant differnce between the groups in age, sex, mortality, weight or dose of vecuronium given (either total or per kg) (Table 1) . The overall syringe flow rates are displayed in Table 2 . This rate of flow was recorded against each integer value of syringe volume over which the syringe plunger passed during that period. The duration of the study necessitated two fillings of the syringes. Data is displayed for each complete syringe filling for each group, and both groups combined ( Figure 3 ). There was no significant difference between the HIB and SIP groups when the all time categories were analysed together (two-way ANOVA P = 0.835). This implies no significant difference in the average level of paralysis between the two groups. There was no significant difference in the SIP group over time (TlO VS T30 or T30 vs T50) (one-way ANOVA P = 0.805), but there was a significant difference in the HIB group with time (P = 0.0035) between TlO and T50. Hourly bolus time recordings were made by the nursing staff themselves. Forty-four per cent of the times recorded were at 60 minute intervals ( Table 2 ). The maximum variation for the expected value is displayed as a percentage change for both the flow rates and the dosing intervals ( Table 2 ). Maximum variation in SIP flow rate was up to ± 33070 over a complete syringe expUlsion and ± 60% when measured on an hourly basis.
Clinical Parameters
There was no difference in TOFCs between the SIP group readings at time no, T30 and T50. There was however a significant difference in the HIB group between 1DFC at no and T30 (P = 0.01), T30 and T50 (P = 0.05) and no and T50 (P = 0.01) ( Table 3) . Dynamic lung compliance, blood pressure, and heart rate measurements did not vary significantly between no, T30 and T50 and there were no significant differences between the two groups.
Additional top-up doses were required because of additional respiratory effort in only two patients (five doses) during the trial period. There was no difference in the number of patients requiring top-up doses, with one in each of the bolus and infusion groups. There was no significant difference in the total number of topups, two in the HIB group and three in the SIP group (M ann Whitney test P = 0.942).
There were no adverse events related to dosing either by infusion or by bolus, and no patient had prolonged paralysis following the cessation of vecuronium.
DISCUSSION
Cost constraints applied to intensive care units are increasing throughout the world 12 and this problem is of a greater significance in a third world environment l3 . The development of an inexpensive infusion device with reasonable safety margins had great appeal for the Baragwanath Intensive Care Unit.
The device is strong and not easily damaged, not dependent on electricity and does not need regular maintenance, all of which are important advantages for equipment used in third world countries. It is very easy to use with minimal possibility of making program errors. Electronic pumps quote reliability figures that are obtained in ideal situations. However in adverse conditions of high viscosity or with back pressure in the line, studies suggest these figures are less accurate and flow rates may vary by as much as 220/0 14 be compounded by the clinical effects of bolus contamination, dilution and other unpredictable variables. For some drugs the minute-by-minute infusion rate may be very important, e.g. catecholamine infusions, but for many drugs this instantaneous accuracy and flexibility is unnecessary. The variation in flow rates for the Springfusor® syringe as described by Wang et all and GO Medical Industries 2 are of the order of 10.5% with a maximum variation of 20% from the expected rates. These values would be suitable for a vecuronium infusion, and many other drugs infused in the Intensive Care Unit.
Our initial aim was to evaluate the Springfusor® infusion device as an infusion device in a clinical setting. Vecuronium administration with neuromuscular monitoring provided a mechanism by which a clinical objective comparison of the Springfusor® 's effectiveness compared to intermittent bolus dosing could be made.
The Springfusor® has its limitations. We found marked variations in the flow rates, outliers being 100% higher and 550/0 lower than its expected rate of flow of 2.5 ml.hr-1 when measured hourly. The average flow rate over an entire syringe load was more constant with an overall 33% maximum variation from the expected rate (Table 2) . These are higher than the figures quoted by Wang et aP and the manufacturer\ but reflect the use of the device in a clinical setting of a busy tertiary referral ICU. As can be seen from the figures, flow rates are more frequently higher than expected and this may reflect the high ambient temperature (23-27 0c) of our ICU affecting the viscosity of the fluid. The increase in flow rate would be expected to be 2.5% per degree Celsius above or below 20°C. The infusion time may be corrected for temperature if deemed necessary.
The variation in flow rate, while seemingly large, must be compared with the variations in the periods between hourly bolus doses given by the nursing staff. Nursing staff were instructed to record the time of administration of the hourly bolus and encouraged to give the doses as close to the hour as possible. Despite their best intentions the nursing workload is of such a nature that the period between doses varied from 40 min to 95 min, the Springfusor® device being less inaccurate, even at high and variable ambient temperature.
The hourly bolus dosage regimen presently used in the Baragwanath Intensive Care Unit involves one nursing intervention per drug per hour administering the drug, as well as the less frequent (4-8 hourly) process of mixing or drawing up the drug. By utilizing the Springfusor® the number of nursing interventions can be reduced to a single intervention every four hours to reload the syringe. Nurses reported that the procedure was simple and quick. This reduces the nursing workload allowing more time for other patient related duties. The process of mixing and drawing up the drugs remains identical. Various workers have commented on the reduced nursing workload associated with continuous infusions. Forbes et all found that one nursing intervention took six minutes compared with 18 minutes for one Springfusor® intervention. An infusion lasting longer than four hours results in reduced nursing time 7
•
Of note is the absence of any alarm device for high or low flows on the Springfusor®. This may be a major restriction to the application of the device within the ICV. During the trial however we experienced no adverse events resulting from either high or low rates of infusion. As the nursing staff checked the infusion device hourly, to document flow rates, any gross variations in the flow rate would have been detected and if necessary corrected.
Our results show that the Springfusor® infusion device using the 2.5 mllhr resistance tubing provides a more constant level of neuromuscular paralysis than the intermittent bolus regimen. There was a significant difference in the TOFC values obtained at each time period within the bolus group but not in the infusion group. Thus the Springfusor® device despite its flow fluctuations provided a more constant level of pharmacological effect than the presently used hourly intermittent bolus regimen.
This trial tested the device for the muscle relaxant vecuronium, and the neuromuscular monitoring provided a sensitive measure of changes in the therapeutic end point. We have utilized the device for infusions of mixtures of sedatives, analgesics and muscle relaxants in both adult and paediatric patients. The Spring-fusor® should provide a more constant therapeutic level of each of these drugs. This may translate to improved patient care.
A wide variety of drugs and diseases alters the volume of distribution as well as duration of action of vecuronium. In this study the body weights of the patients were recorded at the time of the study and therefore may not reflect their true premorbid body mass. Hence in these critically ill patients a dose derived from gross body mass could be expected to correlate poorly with clinical effect. Many other factors contribute to abnormalities in peripheral nerve function in sepsis and multiple organ dysfunction l5
• To eliminate these confounding factors we titrated the dose of vecuronium against a clinical response to obtain an appropriate level of paralysis before randomization (Figure 2 ), after which we started the blinded infusions.
There are case reports of extended paralysis resulting from the use of vecuronium in the ICU I 6-18. Routine maintenance of TOFCs at a constant level of 2 or 3 may prevent excessive paralysis and may prevent extended weakness. It may also prevent unexpected sudden reversal of paralysis in high-risk patients. As our normal clinical practice is to use heavy sedation followed by paralysis when required, this finding is not surprising. Similarly there was no significant difference in the number of additional top-up doses required. Although there was a significant variation in the neuromuscular results (as measured by TOFC) of the bolus group when compared with the infusion group, this did not translate to a difference in any clinical or physiological parameter. Measurements of heart rate, blood pressure, and dynamic lung compliance did not vary significantly in either group and no difference between the bolus group and the infusion group could be shown.
CONCLUSION
There was significant variation in the Springfusor® performance but this variation was less than the period variation of our present hourly bolus regimen. The absence of any adverse events during the trial, the Springfusor® 's ability to provide a more constant pharmacological effect than the hourly bolus regimen, the reduction in nursing time and the low relative cost of the system lead us to the conclusion that the device has advantages in the administration of paralysis and sedation in the ICV.
Despite the more constant neuromuscular paralysis of continuous infusion we were unable to show any clinical advantage following a vecuronium infusion over intermittent hourly bolus dosing.
